BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2225 related articles for article (PubMed ID: 14613270)

  • 1. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
    Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ
    Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.
    Manicourt DH; Poilvache P; Van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
    Arthritis Rheum; 2000 Feb; 43(2):281-8. PubMed ID: 10693867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathobiology of focal lesion development in aging human articular cartilage and molecular matrix changes characteristic of osteoarthritis.
    Squires GR; Okouneff S; Ionescu M; Poole AR
    Arthritis Rheum; 2003 May; 48(5):1261-70. PubMed ID: 12746899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage.
    Kobayashi M; Squires GR; Mousa A; Tanzer M; Zukor DJ; Antoniou J; Feige U; Poole AR
    Arthritis Rheum; 2005 Jan; 52(1):128-35. PubMed ID: 15641080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response.
    Kim TH; Stone M; Payne U; Zhang X; Ionescu M; Lobanok T; King L; Poole AR; Inman RD
    Arthritis Rheum; 2005 Mar; 52(3):885-91. PubMed ID: 15751093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1).
    Dahlberg L; Billinghurst RC; Manner P; Nelson F; Webb G; Ionescu M; Reiner A; Tanzer M; Zukor D; Chen J; van Wart HE; Poole AR
    Arthritis Rheum; 2000 Mar; 43(3):673-82. PubMed ID: 10728762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis.
    Lohmander LS; Ionescu M; Jugessur H; Poole AR
    Arthritis Rheum; 1999 Mar; 42(3):534-44. PubMed ID: 10088777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis.
    Ishiguro N; Ito T; Ito H; Iwata H; Jugessur H; Ionescu M; Poole AR
    Arthritis Rheum; 1999 Jan; 42(1):129-36. PubMed ID: 9920023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.
    Lark MW; Bayne EK; Flanagan J; Harper CF; Hoerrner LA; Hutchinson NI; Singer II; Donatelli SA; Weidner JR; Williams HR; Mumford RA; Lohmander LS
    J Clin Invest; 1997 Jul; 100(1):93-106. PubMed ID: 9202061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis.
    Fraser A; Fearon U; Reece R; Emery P; Veale DJ
    Arthritis Rheum; 2001 Sep; 44(9):2024-8. PubMed ID: 11592363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential matrix degradation and turnover in early cartilage lesions of human knee and ankle joints.
    Aurich M; Squires GR; Reiner A; Mollenhauer JA; Kuettner KE; Poole AR; Cole AA
    Arthritis Rheum; 2005 Jan; 52(1):112-9. PubMed ID: 15641059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis.
    Danning CL; Illei GG; Hitchon C; Greer MR; Boumpas DT; McInnes IB
    Arthritis Rheum; 2000 Jun; 43(6):1244-56. PubMed ID: 10857783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix homeostasis in aging normal human ankle cartilage.
    Aurich M; Poole AR; Reiner A; Mollenhauer C; Margulis A; Kuettner KE; Cole AA
    Arthritis Rheum; 2002 Nov; 46(11):2903-10. PubMed ID: 12428230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis.
    Ishiguro N; Ito T; Oguchi T; Kojima T; Iwata H; Ionescu M; Poole AR
    Arthritis Rheum; 2001 Nov; 44(11):2503-11. PubMed ID: 11710706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13.
    Wu W; Billinghurst RC; Pidoux I; Antoniou J; Zukor D; Tanzer M; Poole AR
    Arthritis Rheum; 2002 Aug; 46(8):2087-94. PubMed ID: 12209513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway.
    Yasuda T; Poole AR
    Arthritis Rheum; 2002 Jan; 46(1):138-48. PubMed ID: 11817586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis.
    Kim WU; Yoo WH; Park W; Kang YM; Kim SI; Park JH; Lee SS; Joo YS; Min JK; Hong YS; Lee SH; Park SH; Cho CS; Kim HY
    J Rheumatol; 2000 Mar; 27(3):575-81. PubMed ID: 10743792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N; Juillet F; Garnero P
    Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 112.